title: Systematic review of tapentadol in chronic severe pain.
abstract: OBJECTIVE
  A systematic review of chronic pain treatment with strong opioids (step 3 WHO pain ladder) and a comparison to a new drug recently approved for the treatment of severe chronic pain in Europe, tapentadol (Palexia, Nucynta*), were performed.
  
  
  METHODS
  Thirteen electronic databases were searched as well as a number of other sources from 1980 up to November 2010 for relevant randomized controlled clinical trials in chronic moderate and severe pain investigating at least one step 3 opioid. Chronic pain could be nociceptive or neuropathic, malignant or non-malignant, all systemic administrations were considered as well as trials of different lengths. Two separate analyses were performed, one only for trials which reported (at least as sub-groups) the outcome in patients with severe pain, the other including both moderate and severe pain conditions. With the exception of the direct comparison between tapentadol, oxycodone and placebo, indirect comparisons were performed based on a network analysis. Trials with an enriched or an enriched withdrawal design were excluded. Primary (pain intensity) and a number of secondary endpoints were evaluated, including pain relief (30% and 50%), patient global impression of change, quality of life, quality of sleep, discontinuations, as well as serious adverse events and selected adverse events.
  
  
  RESULTS
  Only 10 trials were eligible for analysis of patients with severe pain (eight investigating tapentadol and two trials comparing buprenorphine patch vs placebo). For moderate and severe pain, 42 relevant trials were identified and indirect comparisons with transdermal buprenorphine, transdermal fentanyl, hydromorphone, morphine, and oxymorphone were performed. This report focuses on the network analysis. Tapentadol showed statistically favourable results over oxycodone for pain intensity, 30% and 50% pain relief, patient global impression of change (PGIC), and quality of life. Furthermore, some of the most important adverse events of chronic opioid treatment were significantly less frequent with tapentadol as compared to oxycodone, i.e. constipation, nausea, and vomiting; discontinuations due to these adverse events were found significantly reduced with tapentadol. Similar results were obtained for the network analysis, i.e. tapentadol was superior for the primary outcome (pain intensity) to hydromorphone and morphine, whereas fentanyl and oxymorphone showed trends in favour of these treatments. Significantly less frequent gastrointestinal adverse events of tapentadol were observed in comparison with fentanyl, hydromorphone, morphine, and oxymorphone, apparently leading to significantly reduced treatment discontinuations (for any reason).
  
  
  CONCLUSIONS
  Taken together, the benefit-risk ratio of tapentadol appears to be improved compared to step 3 opioids.
authors: Kleijnen Systematic Reviews Ltd, York, UK. rob@systematic-reviews.com
authors: Rob
authors: R
authors: Riemsma
authors: Carol
authors: C
authors: Forbes
authors: Julie
authors: J
authors: Harker
authors: Gill
authors: G
authors: Worthy
authors: Kate
authors: K
authors: Misso
authors: Michael
authors: M
authors: Schäfer
authors: Jos
authors: J
authors: Kleijnen
authors: Steffen
authors: S
authors: Stürzebecher
mesh_terms: D059350:Chronic Pain / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D005060:Europe; D006801:Humans; D010147:Pain Measurement; D010636:Phenols / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D000077432:Tapentadol
chemical_list: D010636:Phenols; D000077432:Tapentadol